MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00259-025-07699-w

Медицинская библиотека · European journal of nuclear medicine and molecular imaging · 2025

PSMA PET/CT for the detection of prostate cancer biochemical recurrence after primary radiation therapy: is it time to review the Phoenix criteria?

Evangelista Laura, Vallone Carlo, Guglielmo Priscilla, Damiani Sara, Jandric Jelena, Brignoli Andrea, Marenco Manuela, Martino Francesco, Di Cristina Luciana, Franzese Ciro, Mazzola Rosario

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

INTRODUCTION

Biochemical recurrence (BCR) in prostate cancer (PCa) after definitive radiotherapy (RT) is defined by a PSA rise ≥ 2.0 ng/mL (Phoenix criteria, Pc). In clinical settings, PSMA PET/CT has demonstrated the ability to identify recurrent disease in case of PSA values remain below this threshold. This retrospective, multicentre study evaluated PSMA PET/CT in patients with rising PSA below the Phoenix-threshold.

MATERIALS AND

METHODS

We retrospectively analysed PCa patients who underwent PSMA PET/CT for rising PSA below Pc in the period 2020-2023. Patients with prior recurrence treatments were excluded. PSMA PET/CT findings were classified by prostate cancer molecular imaging standardized evaluation (PROMISE) score and stratified by D'Amico risk. Treatment decisions were extracted from clinical records. A non‑parametric statistical analysis was employed (MedCalc® software).

RESULTS

Sixty patients were included (median age 79 years, IQR: 75-82). Median PSA value was 1.25 ng/ml (range 0.12-5.02), and median PSA doubling time was 11.8 months (range 0-87.9). The overall PSMA PET/CT detection rate was 71.7% (n = 43/60). Of those with positive scans, 81% (n = 35/43) were oligo‑metastatic and 19% (n = 8/43) were multi‑metastatic. According to the PROMISE score, 10 (23%) patients had only local recurrence, 10 (23%) only pelvic lymph node disease, 10 (23%) only distant metastases, 13 (31%) had local and distant disease (both lymph nodes and bone metastases). By D'Amico risk classification, 83.9% (30/35) of unfavourable intermediate/high‑risk patients had a positive PET, compared with 52.0% (13/25) of low/favourable intermediate‑risk patients (chi squared, p < 0.05). Follow‑up data were available for 54 patients (90%). In 92.6% (n = 50/54), PET findings guided therapy choice: 97% (n = 38/39) of PET‑positive patients received additional treatment (hormonal therapy, RT, or chemotherapy), whereas 80% (n = 12/15) of PET‑negative patients were managed with watchful waiting (chi-square, p < 0.001).

CONCLUSIONS

PSMA PET/CT detects PCa recurrence in about 72% of patients with PSA rises below Phoenix-threshold. By identifying disease at an earlier stage, many patients may become eligible for salvage or metastasis-directed therapies.

Для цитирования: Evangelista Laura, Vallone Carlo, Guglielmo Priscilla, Damiani Sara, Jandric Jelena, Brignoli Andrea, Marenco Manuela, Martino Francesco, Di Cristina Luciana, Franzese Ciro, Mazzola Rosario. PSMA PET/CT for the detection of prostate cancer biochemical recurrence after primary radiation therapy: is it time to review the Phoenix criteria?. European journal of nuclear medicine and molecular imaging. 2025. DOI: 10.1007/s00259-025-07699-w.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.